Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
Antonella Castagna, Franco Maggiolo, Giovanni Penco, David Wright, Anthony Mills, Robert Grossberg, Jean-Michel Molina, Julie Chas, Jacques Durant, Santiago Moreno, Manuela Doroana, Mounir Ait-Khaled, Jenny Huang, Sherene Min, Ivy Song, Cindy Vavro, Garrett Nichols, Jane M Yeo, VIKING-3 Study Group, J Aberg, B Akil, J R Arribas, J-G Baril, J L Blanco Arévalo, F Blanco Quintana, G Blick, V Boix Martínez, O Bouchaud, T Branco, U F Bredeek, M Castro Iglesias, N Clumeck, B Conway, E DeJesus, J-L Delassus, P De Truchis, G Di Perri, M Di Pietro, J Duggan, C Duvivier, R Elion, J Eron, D Fish, J Gathe, R Haubrich, H Henderson, C Hicks, L Hocqueloux, S Hodder, C-B Hsiao, C Katlama, M Kozal, P Kumar, S Lalla-Reddy, A Lazzarin, F Leoncini, J M Llibre, K Mansinho, P Morlat, K Mounzer, M Murphy, C Newman, T Nguyen, B Nseir, P Philibert, G Pialoux, I Poizot-Martin, M Ramgopal, G Richmond, D Salmon Ceron, P Sax, A Scarsella, M Sension, P Shalit, L Sighinolfi, L Sloan, C Small, D Stein, K Tashima, P Tebas, C Torti, M Tribble, D Troisvallets, C Tsoukas, P Viciana Fernández, D Ward, D Wheeler, T Wilkin, G-P Yeni, J Louise Martin-Carpenter, Gina Uhlenbrauck, Antonella Castagna, Franco Maggiolo, Giovanni Penco, David Wright, Anthony Mills, Robert Grossberg, Jean-Michel Molina, Julie Chas, Jacques Durant, Santiago Moreno, Manuela Doroana, Mounir Ait-Khaled, Jenny Huang, Sherene Min, Ivy Song, Cindy Vavro, Garrett Nichols, Jane M Yeo, VIKING-3 Study Group, J Aberg, B Akil, J R Arribas, J-G Baril, J L Blanco Arévalo, F Blanco Quintana, G Blick, V Boix Martínez, O Bouchaud, T Branco, U F Bredeek, M Castro Iglesias, N Clumeck, B Conway, E DeJesus, J-L Delassus, P De Truchis, G Di Perri, M Di Pietro, J Duggan, C Duvivier, R Elion, J Eron, D Fish, J Gathe, R Haubrich, H Henderson, C Hicks, L Hocqueloux, S Hodder, C-B Hsiao, C Katlama, M Kozal, P Kumar, S Lalla-Reddy, A Lazzarin, F Leoncini, J M Llibre, K Mansinho, P Morlat, K Mounzer, M Murphy, C Newman, T Nguyen, B Nseir, P Philibert, G Pialoux, I Poizot-Martin, M Ramgopal, G Richmond, D Salmon Ceron, P Sax, A Scarsella, M Sension, P Shalit, L Sighinolfi, L Sloan, C Small, D Stein, K Tashima, P Tebas, C Torti, M Tribble, D Troisvallets, C Tsoukas, P Viciana Fernández, D Ward, D Wheeler, T Wilkin, G-P Yeni, J Louise Martin-Carpenter, Gina Uhlenbrauck
Abstract
Background: The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose.
Methods: VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INI-resistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA <50 c/mL at week 24.
Results: Mean change in HIV-1 RNA at day 8 was -1.43 log10 c/mL, and 69% of subjects achieved <50 c/mL at week 24. Multivariate analyses demonstrated a strong association between baseline DTG susceptibility and response. Response was most reduced in subjects with Q148 + ≥2 resistance-associated mutations. DTG 50 mg BID had a low (3%) discontinuation rate due to adverse events, similar to INI-naive subjects receiving DTG 50 mg once daily.
Conclusions: DTG 50 mg BID-based therapy was effective in this highly treatment-experienced population with INI-resistant virus.
Clinical trials registration: www.clinicaltrials.gov (NCT01328041) and http://www.gsk-clinicalstudywww.gsk-clinicalstudyregister.com (112574).
Keywords: DTG; dolutegravir; elvitegravir resistance; integrase inhibitor; raltegravir resistance.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.
References
- Raffi F, Rachlis A, Stellbrink H-J, et al. for the SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735–43.
- Cahn P, Pozniak AL, Mingrone H, et al. for the extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700–8.
- Walmsley S, Antela A, Clumeck N, et al. for the SINGLE Investigators. Dolutegravir plus abacavir–lamivudine for the initial treatment of HIVP 1 infection. N Engl J Med. 2013;369:1807–18.
- Tivicay US prescribing information. 2013. Available at: . Accessed 6 January 2014.
- Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55:813–21.
- Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Aquir Immune Defic Syndr. 2012;61:297–301.
- Eron JJ, Clotet B, Durant J, et al. for the VIKING Study Group. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis. 2013;207:740–8.
- Division of AIDS, National Institute of Allergy and Infectious Diseases. Division of AIDS table for grading the severity of adult and pediatric adverse events. Available at: . Accessed 23 August 2013.
- Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006;42:1639–46.
- Stanford University. HIVdb (Integrated Genotypic Resistance Interpretation Systems) Available at: Accessed 18 September 2013.
- Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21–7.
- Center for Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for industry: human Immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment, revision 1, June 2013. Available at: . Accessed 23 August 2013.
- Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J. 2011;45:291–300.
- Akaike H. Information measures and model selection. Proceedings of the 44th Session. Bull Int Statist Inst. 1983;50:277–90.
- Vavro CL, Huang J, Underwood MR, Ait-Khaled M, Sievers J, Yeo JM. Integrase genotypic and phenotypic predictors of antiviral response to dolutegravir (DTG) in subjects with resistance to integrase inhibitors (INIs) [abstract 29]. Program and abstracts of the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies (Toronto); 2013. A37.
- Clotet B, Bellos N, Molina J-M, et al. for the POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–78.
- Hicks CB, Cahn P, Cooper DA, et al. for the RESIST investigator group. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomised Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466–74.
- Madruga JV, Cahn P, Grinsztejn B, et al. for the DUET-1 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38.
- Lazzarin A, Campbell T, Clotet B, et al. for the DUET-2 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48.
- Cahn P, Haubrich J, Leider J, et al. Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) versus placebo in treatment-experienced HIV-1-infected patients. Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago); Washington, DC. American Society for Microbiology; 2007.
- Steigbigel RT, Cooper DA, Kumar PN, et al. for the BENCHMRK Study Teams. Raltegravir with optimised background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–54.
Source: PubMed